Agent and method of treating exudative otitis media in children
SUBSTANCE: what is presented is a method of treating exudative otitis media in children with the preparation Imunofan (synthetic hexapeptide with an immunoregulatory action). With underlying conventional treatment using antihistaminic, mucolytic and vasoconstrictive agents, politserisation, ear drum pneumassage, and laser therapy, the immunomodulator Imunofan is introduced intranasally into the children aged 3 to 7 years old according to the schedule: 1 dose (50 mcg) into each nostril 2 times a day daily for 7 days, then 1 dose (50 mcg) into each nostril 1 time a day (at bedtime) daily for 14 days, and further again 1 dose (50 mcg) into each nostril 2 times a day daily for 7 days.
EFFECT: reducing the length of treatment, the probability of recurrent otitis, the number of complications and enabling a possibility to avoid surgical intervention.
1 dwg, 2 tbl
The invention relates to medicine, namely to otorhinolaryngology, and can be used in the treatment of exudative otitis media (OME) in children.
The known method of treatment of exudative otitis media by application of an intranasal spray mometasone furoate (Nasonex). The introduction is carried out by splashing in the nose 1 dose (50 mcg) in each nostril 2 times a day for one month . The disadvantage of this method is expressed immunosuppressive action of Nasonex. Being the analogue of glucocorticoid hormones, Nasonex may cause serious side effects, such as reduction of local and General immunity. There is also a possibility undesirable system resorptive effects on the body .
Also known a method for the treatment of exudative otitis media by application of an intranasal spray preparation from bacterial lysates IRS 19. Used intranasally, by aerosol administration 1 dose in each nostril 2-5 times a day to 3-4 weeks [2, 3, 10]. The disadvantage of this method is the low spectrum efficiency (generation mainly antibacterial immunity, the lack of initial antiviral activity, the need for long-term treatment, a high probability of recurrence of otitis media). When using medicines IRA� 19 may experience increased body temperature to 39°C and above, abdominal pain, nausea, vomiting, diarrhea, runny nose, cough [8, 14].
The closest to the claimed is a method for the treatment of exudative otitis media by instillation into the nose of immunomodulator "Derinat" (dezoksiribonukleata sodium). Patients during administration of antibacterial, mucolytic, vasoconstrictor and proteolytic agents in each half of nose instill 3 drops 3 times a day 1.5% solution of dezoksiribonukleata sodium within 2-3 weeks [1, 12]. The disadvantage of this method is the possibility of a hypersensitive due to the animal origin of dezoksiribonukleata sodium (from milt of sturgeon and salmonids), which limits its use in certain patient population. With injections Derinat possible fever up to 37,2-37,3°C, observed pain, infiltration and clonic twitching of muscles .
A new technical result - improving the efficiency of treatment of exudative otitis media due to the clear reduction of recurrence and the number of complications.
Another technical result - expanding Arsenal of drugs for the treatment of exudative otitis media in children.
To achieve the technical result in the method of treatment of exudative otitis media in children, including traditional pharmacotherapy, blowing off of CL�hovah pipes for Catheterization, pneumomassage eardrums, laser therapy and intranasal introduction of immunomodulator, immunomodulator administered drug "Imunofan", 50 μg in each nostril 2 times a day every day for 7 days, then 50 mcg in each nostril once a day, 1 at night, daily, for 14 days and further at 50 µg in each nostril 2 times a day every day for 7 days.
Drug "Imunofan (OOO Scientific-production enterprise "Bionics", Moscow), registration number: LS-002646 from 29.12.2006 G., synthetic Hexapeptide belonging to the group of immunomodulatory agents. Possesses immune, detoxification, hepatoprotective action and causes the inactivation of free radical and peroxide compounds. Enhances antioxidant protection of the organism by stimulating the production of ceruloplasmin, lactoferrin, catalase activity, normalizes lipid peroxidation, inhibits the breakdown of phospholipids of cell membranes and the synthesis of arachidonic acid with subsequent decline in the production of inflammatory mediators. Also activates the phagocytosis and destruction of intracellular bacteria and viruses, restores the indices of cellular and humoral immunity, enhances the production of specific antibodies, stimulates IgA with its inherent drawbacks�knosti. The drug approved for local use and comes in a metered nasal spray, available in the use, safe .
Known to use of the drug "Imunofan" in the treatment of patients with chronic obstructive pulmonary disease. Patients in addition to conventional treatment was administered intramuscularly 1 ml of 0.005% solution Imunofana 1 time per day, at intervals through day 7 of injections per course of treatment [6, 7].
Drug "Imunofan" is also used in the treatment of patients with opportunistic infection. Imunofan administered to patients intramuscularly with 1.0 ml (0.05 mg) every two days - 5 injections, then once in four days - 5 injections .
Known to use of the drug "Imunofan" in the treatment of frequently ill children. Sick in addition to basic therapy was administered intramuscularly with 0.5 ml of 0.005% solution every other day, 10 injections [9, 13].
Analysis of information sources showed that the drug "Imunofan" in the treatment of diseases of the middle ear in children have not been applied, no information about its impact on the course of ENT pathology in children.
Our proposed method is as follows.
In addition to the traditional treatment using antihistamines, mucolytic and vasoconstrictor, blowing auditory tube by Catheterization, pneumomassage eardrums and laser�therapy, intranasally administered drug "Imunofan" children from 3 to 7 years according to the scheme: 1 dose (50 mcg) in each nostril 2 times a day every day for 7 days, then 1 dose (50 mcg) in each nostril 1 time a day (at night) daily for 14 days and then again 1 dose (50 mcg) in each nostril 2 times a day every day for 7 days.
Intranasal route of administration of the drug is available, non-traumatic, which is very important in the treatment of children.
The need for the use of the drug "Imunofan" stems from the fact that EDF is a chronic disease of the middle ear, accompanied by a pronounced decrease in local innate immunity. In this regard, short-term courses of immunomodulatory drugs is not always justified. It is generally accepted point of view, when the diseases of the middle ear immunomodulators long courses are assigned, for example, ribomunyl scheme is applied before 6 months, broncho-munal - up to 3 months [14, 15].
During the first 7 days of taking the drug is an active response of the organism, enhanced phagocytic-macrophage reaction of nonspecific immunity. Considering this, the use of the drug in the IRB less than 7 days nucleobase because of insufficient time to develop an adequate response of innate immunity. Main�ISEE the use of the drug is necessary to stabilize work immunnnoy system, restoration of disturbed cellular and humoral level, increasing production of specific antibodies. The choice of this regimen is also due to trapanotto pharmacological action Imunofana prolonging its therapeutic effect for up to 4 months [7, 14].
The new property of the drug in the treatment of exudative otitis media in children was discovered through analysis of the results of clinical observations.
The mode method is also based on the analysis of data from clinical studies performed at the TF fsbi "Scientific clinical center of otorhinolaryngology" in the treatment of 40 patients children aged from three to seven years with chronic exudative otitis media (HESA).
By randomization, all patients were divided into two equal groups: a control group (patients who did not receive immunocorrection) and primary (patients treated using immune). Patients in the control group received conventional treatment: antihistamines (erius), mucolytic (ATT), vasoconstrictor (adriana) funds, mechanotherapy (blowing auditory tube by Catheterization, pneumomassage eardrums), the laser in the nose and endourology electrofanatik with 3% KI. Patients of the main group in addition to the traditional treatment was administered intranasal spray Imunofan according to the scheme: 1 dose (50 mcg) per nostril 2 times a day every day for 7 days then 1 dose (50 mcg) in each nostril 1 time a day (at night) daily for 14 days and then again 1 dose (50 mcg) in each nostril 2 times a day every day for 7 days.
Evaluation of the clinical recovery of the patients in both groups were carried out according to the following criteria: lack of fullness in the ear, normalization otomicroscopic painting, improvement thresholds of auditory perception according to audiometry and restore the ventilation function of the Eustachian tube.
Along with General clinical examination was carried out cytochemical and cytological examination before and after treatment: determined the content of myeloperoxidase in neutrophils in peripheral blood smears stained according to the method Gracham-Knoll, and evaluated the degree of destruction of the epithelium of the mucous membrane of the nasal cavity by nazalnam strokes.
The results of the study
When analyzing the data tone threshold audiometry was estimated the average threshold of conducting sounds to 4 speech frequencies are 0.5, 1, 2 and 4 kHz. The average threshold of air conduction on the voice frequencies of the patients in both clinical groups before therapy was 32,38±4,28 dB. Re audiological examination was conducted on the 30th day.
The improved hearing, reflecting the dynamics of the disease depending on the regimens presented in table 1. Between�ropeway analysis of audiometric parameters in patients of HASO allowed us to obtain statistically significant (P< 0,05) differences at 30 days, indicating a more rapid positive dynamics of the hearing on the background of immunocorrection in comparison with the control group.
According to tympanometry for patients with immunocorrection for 30 days significantly improved the patency of the auditory tube in 85% of patients (17 children). In the group of patients not receiving "Imunofan", improvement was registered in 35% of cases (7 children) (P<0.05) and in three patients at the end of the month the observation was determined exudate in the tympanic cavity, which was confirmed type b tympanograms V.
Cytological and cytochemical examination, conducted prior to the initiation of conservative treatment, showed that for patients in both clinical groups characterized by similar changes of the parameters: the predominance of cells with II and III degree of destruction of epithelial cells, low content of myeloperoxidase in neutrophils peripheral blood.
Fig.1 shows epithelioma nasal smears in children with OME treated differently.
The study showed that in smears from the mucous membrane of the nasal cavity in the group of children who took a basic regimen, a month has increased the destructive changes in the epithelial cells. This was manifested in the increase in the number of epithelial cells with severe damage (Fig. 1), which indicates continuing on�irennoj resistance of epithelial layer after a course of basic therapy. Analysis of the results of the study of children treated in the composition of basic therapy "Imunofan" revealed a high prevalence among the epithelial cells weakly damaged epithelial cells and a decrease in the number of cells with marked signs of degradation (Fig. 1), indicating the restoration of the integrity of epithelial cover.
Study the content of myeloperoxidase in neutrophils of peripheral blood showed a decrease in both clinical groups before treatment, compared with healthy children (table. 2). The use of traditional treatment regimens did not lead to the restoration of the functional activity of neutrophilic granulocytes. Therapy using imunofana led to a significant increase in the content of myeloperoxidase in neutrophils in the early periods of observation (1 month). After 3 months of treatment, this indicator decreased, but remained higher value (20%) compared to the comparison group (table. 2).
Further monitoring of patients was performed within 6 months. In 6 (30%) patients of group I in a given period there was a relapse of the disease, while in patients of group II, treated with immunocorrective therapy of recurrence.
The clinical examples demonstrate the effectiveness of the method.
Example 1. Patient M., age 6, was admitted with complaints for�oannot, hearing loss on both sides. From the anamnesis: on the background of frequent colds mother began to notice that the child asks and complains about ear congestion and periodic feeling of transfusion fluids in the ears. ENT doctor at the clinic prescribed treatment: antibiotic therapy, secretolytic therapy, vasoconstrictor nose drops, mechanotherapy, physiotherapy. The effect is insignificant, the patient is directed to be admitted to the ENT Department with a diagnosis of bilateral chronic otitis media with effusion.
Prescribed treatment according to the proposed method: Muko-, sekretolitiki, mechanotherapy (blowing auditory tube by Catheterization, pneumomassage eardrums), intranasal introduction Imunofana according to the scheme: 1 dose (50 mcg) in each nostril 2 times a day every day for 7 days, then 1 dose (50 mcg) in each nostril 1 time a day (at night) daily for 14 days and then again 1 dose (50 mcg) in each half of the nose 2 times a day every day for 7 days.
On the ninth day the patient has no complaints, the hearing was restored. If otomicroscopy eardrum normal color, markings clear. According to audiometry hearing thresholds within normal limits. Normalization of pressure in the middle ear and restore the mobility of the eardrum (**tympanogram (A). In perio� observations up to six months of relapse did not occur.
Example 2. Patient F., aged 5, was admitted to the ENT clinic with a diagnosis of bilateral chronic otitis media with effusion. From history: 4 months ago in terms of children's ENT Department were treated by bilateral acute exudative otitis media - antibiotic therapy, vasoconstrictor nose drops, Muko-, sekretolitiki, mechanotherapy (blowing auditory tube by Catheterization, pneumomassage eardrums). Was discharged in good condition, had no complaints, the hearing was restored. A month ago was to reiterate ear congestion, and later there was a crackling sound, the feeling of transfusion fluid and tinnitus.
If otomicroscopy: eardrum cloudy with a yellowish tinge, there is a level of fluid in the tympanic cavity from both sides. According to audiometry bilateral conductive hearing loss (I-II degree. * * Tympanogram type b from both sides - the presence of fluid in the middle ear.
Prescribed treatment according to the proposed method Muko-, sekretolitiki, mechanotherapy (blowing auditory tube by Catheterization, pneumomassage eardrums), intranasal introduction "Imunofana" according to the scheme: 1 dose (50 mcg) in each nostril 2 times a day every day for 7 days, then 1 dose (50 mcg) in each nostril 1 time a day (at night) daily for 14 days and the dal� again 1 dose (50 mcg) in each half of the nose 2 times a day every day for 7 days.
Upon further observation, subjectively, on the tenth day of the hearing has significantly improved, noise and transfusion in the ears stopped. OTO-eardrum normal configuration. At the time of normal discharge compliance conductive apparatus (type A), audiometric data in the normal range. Upon further observation of the patient within 6 months of disease recurrence was not.
Thus, the estimation of the parameters of the clinical recovery of the patients surveyed us confirms that topical application of the synthetic immunomodulator "Imunofan" is an effective approach in the treatment of exudative otitis media.
The advantages of the proposed method are: the method is simple, has high efficiency in the conservative treatment of exudative otitis media in children. The use of immune using the proposed scheme the purpose of the drug "Imunofan" reduces the treatment time, reduce the likelihood of recurrence, which is associated, including, acceleration of reparative processes and the restoration of the functional activity of neutrophils. Timely treatment of the IRB with the local application of immunomodulator often allows to avoid surgical intervention. The lack of unwanted effects when using the drug "Imuno�an" all surveyed indicates good tolerability and safety of drugs in children.
Table 1 shows the dynamics of the main indicators of auditory function during treatment of chronic exudative otitis media, dB (M±m) (M - mean value; m is the sampling average error; P - level of significance of differences when compared with the control group at 30 days after treatment; the average threshold of hearing - the average threshold of conduction of sounds on up to 4 speech frequencies are 0.5, 1, 2, and 4 kHz).
Table 2 shows the content of myeloperoxidase in neutrophils of peripheral blood in children with chronic POEs treated differently, Me (Q1-Q3) (statistical significance compared to control p≤0.05; CCS - average cytochemical coefficient; B - basic therapy, And conservative treatment with Imunofan).
Sources of information
1. Diseases of the ear, nose and throat in children: the national guide / ed. by M. R. Bogomilova, R. V. Chistyakova. - M.: GEOTAR-Media, 2008. - 736 p.
2. Garashchenko T. I. Topical bacterial lysates in the prevention and treatment of chronic adenoiditis in children. // Russian otolaryngology. - 2007. - №5 (30). - P. 156-163.
3. Kunikov M. V. Immunopreparat IRS-19 in the treatment of inflammatory diseases of the upper respiratory tract / Kunikov M. V., Vinnikov A. K. // Bulletin of otorhinolaryngology. - 2001. No. 1.- S. 40-42.
4. Kaplina E. N., Che�Nova V. N. The use of Derinat in surgery: a guide for practitioners. Tver: Triad, 2008. 64 p.
5. Karaulov A. V. Clinical and immunological efficacy of imunofana for opportunistic infections / Karaulov A. V. // Attending physician.- 2000. No. 5-6. - Pp. 28-29.
6. Karaulov A. V. a New concept of development of bronchial asthma: immunological and genetic aspects // the Practitioner. 1998, No. 12, pp. 3-4.
7. Karaulov A. V., and Sokurenko S. I. Imunofan: immediate and remote results of treatment of patients with chronic bronchitis // medical Market. 2000. No. 34. S. 21-24.
8. Kladova O. V. et al. Clinico-pathogenetic substantiation of application of IRS-19 in children with bronchopulmonary disease // Adv. Pediatrics. 2002, №3, p. 36-39.
9. Lebedev V. V., Shelepova T. M., O. G. Stepanov, A. Tutelyan V., Danilin, A. B. Imunofan - regulatory peptide in the treatment of infectious and non-infectious diseases / ed. by V. Pokrovsky, I. - M., PRAMENKO, 1998.
10. Lucien L. A. the Possibility of using the drug IRS-19 in otolaryngology / Lucien L. A., Polyakova T. S., Gurov A. V. // Bulletin of otorhinolaryngology. 2001. - No. 3. - P. 21-24.
11. Palchun V. T. Otolaryngology: the national guide / ed. by V. T. Palchun. - Moscow: GEOTAR-Media, 2009. - 960 p.
12. Savenko V. I., Boboshko M. Y., Lopatka A. I., Tzvelev I. D. otitis media with Effusion. SPb.: Dialogue, 2010. 80.
13. Sentsova T. B., P�vagina V. A. Modern immunomodulators in pediatric practice // Russian allergological journal. Sat. articles "sickly children". Materia medica. Moscow, 2006, Pp. 41-43.
14. Directory "Register of medicines of Russia. Radar - 2012
15. Yushkov, V., Yushkov T. A. Rational use of immunomodulators in children // Attending physician. - 2009. - No. 4. - Pp. 55-60.
16. Butler, S. S., van der Voort J. H. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. // Cochrane Database Syst. Rev. - 2006. - Vol.3. - (CD001935).
17. Cengel, M. U. Akyol. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy.// International Journal of Pediatric Otorhinolaryngology. - 2006. - Vol.70. - 639-645.
A method for the treatment of exudative otitis media in children, including traditional pharmacotherapy, blowing off the auditory tube by Catheterization, pneumomassage eardrums, laser therapy and intranasal introduction of immunomodulator, characterized in that the injected drug "Imunofan" according to the scheme: 1 dose of 50 mg in each nostril 2 times a day every day for 7 days then 1 dose of 50 micrograms in each nostril 1 time a day at night daily for 14 days and then again at 50 µg in each nostril 2 times a day every day for 7 days.
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is a pharmaceutical, ear, sterile, preservative-free composition in the form of a transparent aqueous solution, containing 0.01-0.025 % of fluocinilone acetonide optionally in a combination with 0.1-0.8% of ciprofloxacin or its pharmaceutically acceptable salt, a non-ionic surface-active substance, a tonicity-regulating agent and a viscosity-increasing agent.
EFFECT: composition is useful for the prevention and/or treatment of ear inflammation, optionally accompanied with a bacterial infection, and for the introduction of a single dose from a package.
15 cl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.
EFFECT: obtained are the novel derivatives of pyrasole pyridine, useful for the treatment and/or prevention of disorders or states, associated with NADPH-oxidase.
12 cl, 3 tbl, 21 ex
SUBSTANCE: group of inventions refers to medicine and concerns ear-drum or external auditory canal restoration. That is ensured by presented an agent containing a combination of gelatine sponge, basic fibroblast growth factor and fibrin glue, as well as using these ingredients for producing the agent. The method involves placing gelatine sponge containing a therapeutically effective amount of basic fibroblast growth factor within an ear-drum perforation or a defect of soft tissue of the external auditory canal and covering the sponge with fibrin glue.
EFFECT: inventions provide the effective defect closure and tissue restoration, including in the case where common methods are not applicable.
6 cl, 2 dwg, 3 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine. A composition for treating an ear disease is introduced into the tympanic cavity, contains a polyoxyethylene-polyoxypropylene copolymer, an active substance specified in an immunomodulator, a vasopressin antagonist, an ion channel antagonist, a neurokinin receptor antagonist, a serotonin reuptake inhibitor, an NMDA-receptor antagonist, a prostaglandin analogue, a preparation having an effect on the central nervous system, a GABA receptor modulator, a cytotoxic agent, an antioxidant, a glutamate receptor modulator or a calcineurin inhibitor.
EFFECT: invention provides the prolonged release of the active substance into the internal ear for a period of time of at least 7 days.
14 cl, 3 dwg, 114 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: pharmaceutical composition for treating an infection containing mometasone furoate or a solvate thereof, Orbifloxacin, a fatty acid containing 3 to 18 carbon atoms and having a melting point of no more than about 60°; a method of treating an infection in an animal involving administration thereof, using the above composition for preparing a drug for treating the infection in the animal and a therapeutic kit for treating the infection comprising the above composition. The storage stability of the declared composition at room temperature is shown. The examples of the stable formulations of suspensions, e.g. for treating eye infection are provided.
EFFECT: preparing the pharmaceutical composition for treating the infection.
14 cl, 11 tbl, 3 ex
SUBSTANCE: intratympanic composition used for treating an ear disease contains: (a) an antimicrobial agent consisting of a number of particles; and (b) a polyoxyethylene and polyoxypropylene copolymer; the composition (i) is a liquid at room temperature; (ii) has a gelling point within the range of 19°C to 42°C; (iii) has a gel viscosity of 15000 sP to 1000000 sP; (iv) has an osmolarity less than 1000 mOsm/l; and the intratympanic composition release the antimicrobial agent in an ear for at least 5 days, and it is introduced at room temperature.
EFFECT: effective treatment of the ear diseases; the composition is non-toxic and has a non-irritating effect on the ear structures, provides the permanent prolonged release of the active agent with a reduced dose rate and reduces the risk of a potential tympanum damage.
13 cl, 9 tbl, 5 dwg, 30 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and deals with composition for application in treatment of ear diseases by intra-tympanum introduction into membrane of cochlea window or near membrane of cochlea window, which contains, acceptable for ear treatment thermoreversible water gel, which contains polymer of polyoxypropylene and polyoxyethylene and anti-apoptosis agent, slowed release of anti-apoptosis agent into cochlea taking place for, at least, 4 days.
EFFECT: invention ensures constant, slowed, prolonged release of active agent.
10 cl, 26 ex, 5 dwg
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be applicable for surgical management of the patients with an ossicular chain pathology. For this purpose, an ossiculoplasty involves graft fixation by a platelet enriched autoblood plasma bunch taken immediately before the operation That is followed by laser coagulation of the bunch.
EFFECT: technique provides improved functional effect and simplified ossiculoplasty, eliminated allergic reactions, eliminated risk of graft rejection, reduced recurrences due to fixation of the repaired elements, reduced risk of dislocation thereof up to formation of the physiological fixation ensured by middle ear soft tissues regeneration.
SUBSTANCE: pharmaceutical composition, suitable for application in treatment of ear diseases includes acceptable for ear thermoreversable water gel. Pharmaceutical composition consists of anti-inflammatory corticosteroid in form of multiple particles and polyoxypropylene and polyoxyethylene-based polymer. Composition is introduced locally to the subject, suffering from ear disease, by intratympanic introduction on membrane of cochlea window or near it.
EFFECT: composition in accordance with invention ensures prolonged release of anti-inflammatory corticosteroid through membrane of cochlea window into inner ear cochlea during, at least, 5 days after a single introduction.
12 cl, 9 dwg, 9 tbl, 31 ex
SUBSTANCE: invention refers to medicine, namely otorhinolaryngology, and may be used in complex therapy of acute othelcosis. Low-frequency ultrasound is used to introduce ceftriaxone phonophoresis through an eardrum into a tympanic cavity for 10 seconds. Then 5 minutes later, it is followed by the phonophoretic introduction of ceftriaxone and lidase in equal proportions into mastoid, preauricular and submandibular lymph nodes for 15 seconds. The therapeutic course is 5 daily procedures.
EFFECT: method provides higher conservative clinical effectiveness in the patients with acute othelcosis ensured by additional pathogenetic lymphotropic exposure on the region of middle ear.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to oligopeptides, containing the sequence NLSSAEVVV (SEQ ID NO:6), in which one or two amino acids can be substituted, possessing the inducibility of cytotoxic T-cells, their pharmaceutical compositions and application for the production of anti-cancer vaccines.
EFFECT: obtaining pharmaceutical compositions for the production of anti-cancer vaccines.
20 cl, 6 dwg, 1 tbl, 1 ex
SUBSTANCE: thrombocyte aggregation-inhibiting heteromeric peptides based on imidazo[4,5-e]benzo[1,2-c;3,4-c']difuroxane are disclosed: , where R=Phe-Ile-Ala-Asp-Thr; Arg-Tyr-Gly-Asp-Arg; Lys-Ile-Ala-Asp-Asp; His-Ile-Gly-Asp-Asp.
EFFECT: improved properties.
1 dwg, 2 tbl, 4 ex
SUBSTANCE: group of inventions refers to medicine and concerns a method for the delivery of octreotide or its pharmaceutically acceptable salt into an individual, involving implanting the implanted device comprising a polyurethane polymer into the individual; the implanted drug delivery device for the octreotide acetate release by diffusion through a polyurethane polymer.
EFFECT: group of inventions provides high biocompatibility and biostability when used as an implant for the patients for the octreotide delivery to tissues or organs.
4 cl, 3 dwg, 5 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a peptide, a peptide mimetic or an amino acid derivative, which contain di-substituted β-amino acid, wherein each of substituting group in the β-amino acid, which can be identical or different, contains at least 7 non-hydrogen atoms, is lipophilic and contains at least one cyclic group; one or more cyclic groups in the substituting group can be bound or condensed with one or more numbers of cyclic groups in the other substituting groups, and when the cyclic groups are fused so that an aggregate total number of non-hydrogen atoms for these two substituting groups makes at least 12, wherein the above peptide, peptide mimetic or amino acid derivative consist of 1-4 amino acids or length-equivalent sub-units.
EFFECT: preparing the peptide, peptide mimetic or amino acid derivative, which contain the di-substituted β-amino acid.
17 cl, 4 dwg, 10 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and medicine. A compound (I) has an affinity to some subtypes of somatostatin receptors, and therefore can be used as a therapeutically active peptide in developing formulations of therapeutic agents for treating pathological conditions or diseases, which involve one or more somatostatin receptors. Besides, the compound (I) can be used as a peptide used as a carrier in prescription formulations.
EFFECT: what is presented is a new octapeptide compound of general formula (I): H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2.
20 cl, 3 tbl, 25 ex
SUBSTANCE: invention refers to medicine and can be used for the correction of the individual's functional state and performance. That is ensured by administering Semax neuroactive peptide in a dose of two drops in each nasal passage. That is followed by the electric current exposure covering a frontal-mastoid region at pulse length 0.2ms, current intensity 0.8mA and pulse train 800Hz for 40 min. The exposure is combined with at least 10 sessions of hyperbaric oxygenation at pressure 1.6 atm.
EFFECT: method provides the rapid and effective increase of performance in sportsmen, military men and individuals involved in the other professions related to significant physical and mental stress by improving the functions of various regions of brain cortex as a result of the selected complex exposure enabling the substantial vasodilatation and maximum tissue oxygenation.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biochemistry, in particular to cyclic peptide, capable of inducing antibody response. Peptide consists of formula X2X3VGSNK-Z or X3VGSNKG-Z, where X2 represents E, G, Q or K, X3 represents D or N and Z represents agent, stabilising bent, present inside peptide sequence, with peptide being cyclised by covalent bonding of N-end amino acid with Z, where Z represents peptide fragment YNGK. Conjugate, containing said cyclic peptide, conjugated with immunogenic carrier molecule is also claimed. peptide and conjugate, which contains it, can be applied for production of medication or as vaccine against Alzheimer's disease. Methods of obtaining cyclic peptide and conjugate are also claimed.
EFFECT: invention makes it possible to obtain improved, less toxic vaccine against Alzheimer's disease.
8 cl, 11 dwg, 1 tbl, 2 ex
SUBSTANCE: treating acute knee arthritis is ensured by measuring a pre-therapeutic blood lymphocyte percentage in the patient. That requires performing 5 sessions of finger point massage of the points IV.9, XI.34, VII.60, III.36. If the lymphocyte percentage is less than 25%, Myelopidum 6 mg a day is administered additionally every second day, in number of 5 injections.
EFFECT: reducing the clinical manifestations of acute knee arthritis taking into account the immune state.
SUBSTANCE: invention relates to His-Phe-Arg-Trp-Pro-Gly-Pro uniformly labelled with deuterium or yttrium, which can be used in analytical chemistry and biological research.
EFFECT: improved method.
2 tbl, 2 ex
SUBSTANCE: claimed invention relates to modified opiorphin peptides as novel inhibitors of metal-ectopeptidases.
EFFECT: obtaining modified opiorphin peptides.
17 cl, 23 dwg, 1 tbl, 3 ex
FIELD: medicine, cardiology.
SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.
EFFECT: higher efficiency of therapy.